The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation of nivolumab 480 mg Q4W with better survival than other nivolumab monotherapy schedule in metastatic melanoma patients.
 
Ester Simeone
No Relationships to Disclose
 
Domenico Mallardo
No Relationships to Disclose
 
Diana Giannarelli
No Relationships to Disclose
 
Lucia Festino
No Relationships to Disclose
 
Vito Vanella
No Relationships to Disclose
 
Claudia Trojaniello
No Relationships to Disclose
 
Maria Grazia Vitale
No Relationships to Disclose
 
Marco Palla
No Relationships to Disclose
 
Luigi Scarpato
No Relationships to Disclose
 
Mariaelena Capone
No Relationships to Disclose
 
Gabriele Madonna
No Relationships to Disclose
 
Marcello Curvietto
No Relationships to Disclose
 
Assunta Esposito
No Relationships to Disclose
 
Federica Hauber
No Relationships to Disclose
 
Fabio Sandomenico
No Relationships to Disclose
 
Ernesta Cavalcanti
No Relationships to Disclose
 
Corrado Caraco
No Relationships to Disclose
 
Paolo Mainardi
No Relationships to Disclose
 
Antonio Maria Grimaldi
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Speakers' Bureau - Merck Serono; Merck Sharp & Dohme
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche; Sun Pharma
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Immunocore; Incyte; Italfarmaco; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; Syndax; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme